Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer

PALM BEACH, Fla., March 24, 2022 /PRNewswire/ — FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected…

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

We report here for the first time the initial assessment of the utility of CGP testing for patients with metastatic breast cancer under Japanese universal health insurance system. In the…

Dietrich Analyzes Study Results in Early-Stage Breast Cancer Treatments

During a Targeted Oncology case-based roundtable event, Martin Dietrich, MD, PhD, discussed the MonarchE trial of abemaciclib and the agent’s use in high-risk, early-stage breast cancer. Targeted OncologyTM: What is…

Endocrine therapy de-escalation a possibility for ER-low positive breast cancer

medwireNews: Women with estrogen receptor (ER)-low positive breast cancer may be considered for 2 to 3¬†years of endocrine therapy rather than the standard 5¬†years without a negative impact on disease-free…

A $1.57 million grant funds breakthrough breast cancer prevention and treatment research

Mason researcher Milton Brown is one of only a handful of physician scientists in the United States that holds a PhD in synthetic chemistry and a medical degree. Photo by…

FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

By The ASCO Post Staff Posted: 3/14/2022 10:51:00 AM Last Updated: 3/15/2022 8:32:00 AM On March 11, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant…